Edgewise Common Stock Total Equity from 2010 to 2024

EWTX Stock  USD 17.13  0.37  2.11%   
Edgewise Therapeutics Common Stock Total Equity yearly trend continues to be fairly stable with very little volatility. Common Stock Total Equity will likely drop to 6,050 in 2024. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2010-12-31
Previous Quarter
6.9 K
Current Value
K
Quarterly Volatility
577.70069693
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise main balance sheet or income statement drivers, such as Net Interest Income of 14.9 M, Interest Income of 14.9 M or Depreciation And Amortization of 1.8 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.3. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
This module can also supplement Edgewise Therapeutics' financial leverage analysis and stock options assessment as well as various Edgewise Therapeutics Technical models . Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Edgewise Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Edgewise Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Edgewise Common Stock Total Equity Regression Statistics

Arithmetic Mean5,263
Geometric Mean5,237
Coefficient Of Variation10.98
Mean Deviation421.33
Median5,000
Standard Deviation577.70
Sample Variance333,738
Range1.9K
R-Value0.66
Mean Square Error204,448
R-Squared0.43
Significance0.01
Slope84.82
Total Sum of Squares4.7M

Edgewise Common Stock Total Equity History

2024 6050.0
2023 6900.0
2022 6000.0

About Edgewise Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Edgewise Therapeutics income statement, its balance sheet, and the statement of cash flows. Edgewise Therapeutics investors use historical funamental indicators, such as Edgewise Therapeutics's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Edgewise Therapeutics investors may use each financial statement separately, they are all related. The changes in Edgewise Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Edgewise Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Edgewise Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Total Equity6.9 KK

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Edgewise Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edgewise Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edgewise Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edgewise Therapeutics Stock:
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Edgewise Stock analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Edgewise Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edgewise Therapeutics. If investors know Edgewise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edgewise Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.54)
Return On Assets
(0.17)
Return On Equity
(0.25)
The market value of Edgewise Therapeutics is measured differently than its book value, which is the value of Edgewise that is recorded on the company's balance sheet. Investors also form their own opinion of Edgewise Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Edgewise Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edgewise Therapeutics' market value can be influenced by many factors that don't directly affect Edgewise Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edgewise Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edgewise Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edgewise Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.